Researchers have developed a new technique to pinpoint immune cells in cancer patients that are reactive against their disease. This research could lead to more targeted immune-based therapies for cancer patients. Immunotherapy is a relatively new field of cancer treatment which works by promoting the patient’s immune system to fight against the cancer. Although immune […]
Two separate studies have uncovered insights into why checkpoint-inhibiting immune-oncology (IO) drugs only work for a minority of patients, even when combined with other treatments. The first study uncovered a resistance mechanism within the gut microbiome, while the other relates to cancer cell-produced vesicles.
A second individual has experienced sustained remission from HIV after their treatment ended, scientists from the University of Central London and Imperial College have found.
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
A new report from the University of Pennsylvania School of Veterinary Medicine has expanded what we know about the connection between myeloid-derived immunosuppressor cells (MDSCs) and aggressive disease. Their research has found that blocking the deltaNp63 protein on tumour cells which directs MDSCs to tumour and metastatic sites, or blocking the MDSCs themselves, reduces tumour growth and metastasis in a mouse model of triple-negative breast cancer (TNBC).
The 2018 Nobel Prize for Physiology or Medicine has been awarded to James Allison and Tasuku Honjo for their work on cancer immunotherapy.
Researchers have designed nanoparticles that can be attached to T-cells and release T-cell-stimulating molecules called cytokines, that activate T-cells to attack nearby tumour cells.
Researchers have come up with a tool that offers a means of control over engineered cells, and it comes from a seemingly unlikely source — the hepatitis C genome.
Researchers have identified a new subtype of prostate cancer that occurs in about 7% of patients with advanced disease. This subset of tumours was responsive to immunotherapy treatment.